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Phytic acid, known as myo-inositol (MI) hexakisphosphate, is the principal storage form of phosphorus in many 
plant tissues, especially bran and seeds. Phytases comprise a group of phosphatases that can trim inorganic 
phosphates from phytic acid.  B. subtilis laboratory standard strain 168 and its derivatives exhibit no phytase 
activity, whereas a natto starter secretes significant phytase actively.  
The natto phytase gene was cloned into strain RIK1285, a protease-defective derivative of 168, to construct a 
random library of its N-terminal fusions with 173 different signal peptides identified in the 168 genome. The 
library was screened to assess the efficiency of phytase secretion based on clear zones around colonies on 
plates, which appeared when phytic acid was hydrolyzed.  
The pbp signal peptide enhanced the secretion of the natto phytase most efficiently, i.e., twice that of the 
original signal peptide. The secreted phytase can be one of the enzymatic tools to liberate MI from phytic acid 
contained in agricultural wastes including rice bran. 
As described above, MI is the most abundant inositol stereoisomer in nature and thus supplied cheap. On the 
other hand, scyllo-Inositol (SI) is one of the inositol stereoisomers, rare in the nature, and expected as a 
promising disease-modifying therapeutic agent for Alzheimer's disease.  
B. subtilis 168 has the ability to metabolize inositol stereoisomers, including MI and SI. Previously, we reported 
a B. subtilis cell factory with modified inositol metabolism that converts MI into SI in the culture medium. The 
strain was constructed by deleting all genes related to inositol metabolism and overexpressing key enzymes, 
IolG and IolW. By using this strain, 10 g/l of MI initially included in the medium was completely converted into SI 
within 48 h of cultivation in a rich medium containing 2% (w/v) Bacto soytone. 
When the initial concentration of MI was increased to 50 g/l, conversion was limited to 15.1 g/l of SI. Therefore, 
overexpression systems of IolT and PntAB, the main transporter of MI in B. subtilis and the membrane-integral 
nicotinamide nucleotide transhydrogenase in Escherichia coli respectively, were additionally introduced into the 
B. subtilis cell factory, but the conversion efficiency hardly improved. We systematically determined the amount 
of Bacto soytone necessary for ultimate conversion, which was 4% (w/v). As a result, the conversion of SI 
reached to 27.6 g/l within 48 h of cultivation. 
The B. subtilis cell factory was improved to yield a SI production rate of 27.6 g/l/48 h by simultaneous 
overexpression of IolT and PntAB, and by addition of 4% (w/v) Bacto soytone in the conversion medium. The 
concentration of SI was increased even in the stationary phase perhaps due to nutrients in the Bacto soytone 
that contribute to the conversion process. Thus, MI conversion to SI may be further optimized via identification 
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